m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00344)
Name
6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine
Synonyms
6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamine; CHEMBL311108; CTK7E1320; ZINC13588156; BDBM50137196; AKOS015965750; 6-phenylthieno[3,2-d]pyrimidin-4-ylamine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C12H9N3S
InChI
1S/C12H9N3S/c13-12-11-9(14-7-15-12)6-10(16-11)8-4-2-1-3-5-8/h1-7H,(H2,13,14,15)
InChIKey
WQVHTLKGGYMXIO-UHFFFAOYSA-N
PubChem CID
11499583
TTD Drug ID
D09PLJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). [1], [2]
References
Ref 1 The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-KappaB/MYC signaling network. Oncogene. 2019 May;38(19):3667-3680. doi: 10.1038/s41388-019-0683-z. Epub 2019 Jan 18.
Ref 2 Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. doi: 10.1021/jm0510979.